Pancreatic Cancer Pill Update: Nov. 20 Trial Results, Canada Access and Patient Outlook

Updated: November 20, 2026, 8:06 p.m. UTC.

New results presented today suggest that adding the oral drug daraxonrasib to chemotherapy may help shrink metastatic pancreatic tumors, but the evidence is still early and does not establish that this combination improves survival. For Canadians, there is no confirmed routine-availability date: the United States has approved daraxonrasib for a narrower, previously treated patient group, while Health Canada’s trial portal lists an ongoing phase 3 study at sites in Toronto and Montréal.

The findings were presented at the EORTC-NCI-AACR Symposium in Barcelona, Spain, on Friday, November 20, 2026. The program placed the presentation from 12:00 to 13:30 p.m. Barcelona time, Central European Time (CET, UTC+01:00), or 11:00 a.m. to 12:30 p.m. UTC.

Highlights

  • In a 61-person phase 1/2 cohort, 60.7% had tumors shrink or disappear; median progression-free survival was 12.8 months.
  • The combination is daraxonrasib by mouth plus two intravenous chemotherapy drugs, not a pill-only regimen.
  • Because the new cohort had no randomized chemotherapy-only comparison, its results cannot prove a survival advantage.
  • Canada has no published launch date. A phase 3 daraxonrasib trial is listed as recruiting at three Toronto and Montréal sites, subject to eligibility and site confirmation.
Patient and clinician discuss pancreatic cancer treatment options in a clinic
Illustrative image of a patient consultation; it does not show a trial participant or a specific Canadian clinic.

What did the November 20 pancreatic cancer study find?

The update concerns RMC-GI-102, an early-phase study of daraxonrasib combined with gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic adenocarcinoma. “First-line” here means treatment for metastatic disease before a patient has received another regimen for that advanced stage. The conference report says 61 patients had received the combination by September 28, 2026, with a median follow-up of 18.3 months.

Among those patients, 60.7% had an objective response, meaning their tumors shrank or were no longer detectable on assessment. Complete responses were reported in 8.2%, and 90.2% had disease control, a category that includes stable disease as well as tumor responses. Median progression-free survival (PFS)—the time by which half the group had experienced cancer progression or death—was 12.8 months. The reported 12-month overall survival rate was 76.6%.

These numbers are encouraging, but they are not proof that the combination extends life. RMC-GI-102 is a small, early-phase cohort without a randomized control group. The study’s lead investigator said a larger randomized phase 3 trial is needed to determine whether these results translate into better outcomes than chemotherapy alone.

Is daraxonrasib already approved, and where?

The drug is known by the U.S. brand name RASONQUE. The U.S. Food and Drug Administration approved daraxonrasib on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. That approval rests on RASolute 302, a separate phase 3 trial in previously treated patients—not on the new first-line combination results.

In RASolute 302, median overall survival in the overall study population was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Median PFS was 7.2 months versus 3.6 months. These are group medians from a defined trial population; they are not an estimate of how long a particular person will live, and they should not be directly compared with results from the separate first-line combination cohort.

The FDA said it collaborated with Health Canada under Project Orbis, but also noted that partner regulators may still be reviewing their own applications. Participation in a coordinated review does not mean Canada has approved the drug.

When could Canadian patients get the pill?

There is no reliable public date for routine availability in Canada. Health Canada’s Drug Product Database is the official place to check products authorized for sale, and its Notice of Compliance database records Canadian authorization dates. The official pages reviewed for this article did not provide a Canadian approval or launch date for daraxonrasib. Approval in the United States or Europe does not automatically authorize sale in Canada.

One practical route to ask about is a clinical trial. Health Canada’s Canadian Clinical Trial Search Portal lists RASolute 303, a phase 3 trial comparing daraxonrasib alone or with gemcitabine and nab-paclitaxel against chemotherapy alone. The portal, last updated November 7, lists the trial as recruiting and names Princess Margaret Cancer Centre and Sunnybrook Research Institute in Toronto, plus McGill University’s oncology research program in Montréal. The portal cautions that recruitment can differ by site, so patients should confirm directly and review the eligibility criteria with their oncologist.

For an unapproved drug outside a trial, a treating physician may consider a patient-specific request through Health Canada’s Special Access Program (SAP). This is not a guaranteed or routine access route: the physician must apply, Health Canada assesses each case, and the manufacturer must agree to supply the drug. SAP authorization is not the same as full market approval. Ask the oncology team whether a Canadian trial, standard treatment, or an SAP request is appropriate for the individual situation.

What does the patient outlook look like?

For people with metastatic disease, the new response and PFS figures offer a reason for cautious interest, not a promise of benefit. The combination also includes intravenous chemotherapy, so it does not remove the burdens or side effects of infusion treatment. In the early-phase cohort, commonly reported effects included rash, diarrhea, fatigue, and low blood-cell counts; five percent stopped treatment because of daraxonrasib-related side effects. A clinician can explain how those risks compare with other options and a patient’s health history.

Daraxonrasib is designed to interfere with active RAS signaling, which drives growth in many pancreatic cancers. Its FDA label for the approved monotherapy indication also warns about skin and soft-tissue toxicity, mouth inflammation, diarrhea, gastrointestinal perforation, lung inflammation, and fetal harm. The side-effect profile for a combination can differ from monotherapy and should be discussed with the treating team.

For now, the strongest immediate step for a Canadian patient or caregiver is to ask the oncologist whether the person’s diagnosis, prior treatment, tumor features, and location match an active study such as RASolute 303. A future phase 3 result, a Health Canada submission and decision, and provincial access or coverage are separate milestones. None has a confirmed date for routine Canadian access at this time.

FAQ

Is the pancreatic cancer pill available in Canada now?

Daraxonrasib does not have a confirmed routine Canadian launch date in the official information reviewed. A Canadian clinical trial is listed as recruiting at sites in Toronto and Montréal; patients must meet the study criteria and confirm a site is enrolling.

Does the November 20 result mean the drug doubles survival?

No. The 12.8-month median PFS and 76.6% one-year survival rate came from a 61-person, early-phase combination cohort without a randomized control group. They do not establish a survival benefit. A separate phase 3 trial reported survival results for daraxonrasib monotherapy in previously treated metastatic disease.

Can a Canadian patient request the drug through Health Canada?

A physician may apply through the Special Access Program for an eligible patient, but approval is case-specific, the patient cannot apply directly, and the manufacturer is not required to provide the drug. The treating physician can explain whether this route is appropriate.

Sources

Leave a Comment

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

GTA 6 Gameplay and Features: What’s Confirmed as of November 21, 2026

See what Rockstar has confirmed about GTA 6 gameplay, Jason and Lucia, Leonida’s locations, platforms, visuals, and features—and what remains undisclosed.

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

How to Protect Your Superannuation From AI Phone Scams | November 21, 2026

An AI-generated call about superannuation highlights risks from cold callers and scams. Learn how to verify callers, protect account details, and act if you shared information.

GTA VI Is Out Now: Platforms, Story and What Comes Next — 20 November 2026

GTA VI launched on PS5 and Xbox Series X|S on 19 November. Here is what Australian players need to know about availability, the story, PC status and next steps.

Ellen Fanning’s AI Superannuation Call: What Australians Need to Know on November 20

An AI caller targeting Ellen Fanning’s super details has been reported across Australia. Here’s what the latest reporting and official guidance say to do.

How AI Voice Calls Could Put Australian Super at Risk

An AI caller named Alex has cold-called Australians about switching super funds. Learn how lead generation works and how to protect your retirement savings.

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

UK Emergency Preparedness: Household Essentials You Actually Need | November 20, 2026

Build a practical three-day UK emergency kit with water, no-cook food, light, medicines, and a plan—without panic buying or waste.

Billie Eilish Confirmed for BST Hyde Park 2027: July 3 Date and Ticket Prices

Billie Eilish is confirmed for BST Hyde Park on July 3, 2027. See current ticket prices, presale and general sale dates, and what is still to be announced.

BST Hyde Park 2027: Headliners, Tickets and Confirmed Dates

Bon Jovi, Muse, Billie Eilish and RAYE are among BST Hyde Park 2027’s confirmed headliners. See dates, ticket prices, sale details and what is still to come.

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK Emergency Stockpiling: Essential Grocery Sales Jump After Be Ready Advice | Nov. 20, 2026

UK emergency-preparedness purchases rose after Be Ready advice. See the latest grocery sales data, what it measures, and what the government actually recommends.

Why UK Shoppers Are Stocking Up on Groceries: What the Latest Data Shows (November 20, 2026)

UK food-store sales rose in October as shoppers bought more long-life groceries after the Be Ready campaign. Here’s what the data and official advice mean.